Literature DB >> 17433952

Increased Rho kinase activity in a Taiwanese population with metabolic syndrome.

Ping-Yen Liu1, Jyh-Hong Chen2, Li-Jen Lin2, James K Liao3.   

Abstract

OBJECTIVES: We sought to determine whether Rho kinase (ROCK) activity is increased in a Taiwanese population with metabolic syndrome (MetS).
BACKGROUND: Recent studies suggest that ROCK may be involved in the pathogenesis of MetS, but clinical studies linking ROCK with MetS are lacking.
METHODS: We studied 40 Taiwanese subjects (60% men, mean age 55.5 +/- 5.6 years) who were diagnosed with MetS with National Cholesterol Educational Program Adult Treatment Panel III criteria and 40 age- and gender-matched control subjects. Subject demographics were recorded, and blood samples were obtained.
RESULTS: Compared with control subjects, ROCK activity, as determined by phosphorylation of myosin binding subunit (MBS) in leukocytes, was greater in MetS subjects (mean phospho-MBS/MBS ratio 0.46 vs. 0.35, p = 0.002). A cutoff value for ROCK activity of 0.39 predicted the presence of MetS with specificity and sensitivity rates of 70%. Plasma high-sensitivity C-reactive protein was greater (5.5 mg/l, 95% confidence interval [CI] 3.1 to 7.2 mg/l vs. 2.8 mg/l, 95% CI 1.1 to 3.9 mg/l, p = 0.01) and adiponectin was lower (4.9 microg/ml, 95% CI 3.2 to 6.1 microg/ml vs. 5.9 microg/ml, 95% CI 4.2 to 7.5 microg/ml, p = 0.01) in MetS subjects compared with control subjects, but plasma levels of interleukin-6 and tumor necrosis factor-alpha were not different (p > 0.05 for both). Body mass index, waist circumference, fasting glucose, high-sensitivity C-reactive protein, and triglyceride levels were associated with increased levels of ROCK activity. The risk of increased ROCK activity increased with the number of MetS components (p for trend <0.001).
CONCLUSIONS: Rho kinase activity is increased in Taiwanese subjects with MetS and is associated with each component of MetS and markers of inflammation. These findings suggest that ROCK activity may be a novel serological marker of MetS.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17433952      PMCID: PMC2615567          DOI: 10.1016/j.jacc.2006.12.043

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  32 in total

1.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).

Authors: 
Journal:  JAMA       Date:  2001-05-16       Impact factor: 56.272

2.  Modulation of Rho GTPase signaling regulates a switch between adipogenesis and myogenesis.

Authors:  Raffaella Sordella; Wei Jiang; Guang-Chao Chen; Marcello Curto; Jeffrey Settleman
Journal:  Cell       Date:  2003-04-18       Impact factor: 41.582

3.  The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men.

Authors:  Hanna-Maaria Lakka; David E Laaksonen; Timo A Lakka; Leo K Niskanen; Esko Kumpusalo; Jaakko Tuomilehto; Jukka T Salonen
Journal:  JAMA       Date:  2002-12-04       Impact factor: 56.272

Review 4.  Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies.

Authors: 
Journal:  Lancet       Date:  2004-01-10       Impact factor: 79.321

5.  Active Rho kinase (ROK-alpha ) associates with insulin receptor substrate-1 and inhibits insulin signaling in vascular smooth muscle cells.

Authors:  Najma Begum; Oana A Sandu; Masaaki Ito; Suzanne M Lohmann; Albert Smolenski
Journal:  J Biol Chem       Date:  2001-12-05       Impact factor: 5.157

6.  Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey.

Authors:  Earl S Ford; Wayne H Giles; William H Dietz
Journal:  JAMA       Date:  2002-01-16       Impact factor: 56.272

7.  The metabolic syndrome as predictor of type 2 diabetes: the San Antonio heart study.

Authors:  Carlos Lorenzo; Mayor Okoloise; Ken Williams; Michael P Stern; Steven M Haffner
Journal:  Diabetes Care       Date:  2003-11       Impact factor: 19.112

Review 8.  Adipose tissue, insulin action and vascular disease: inflammatory signals.

Authors:  J S Yudkin
Journal:  Int J Obes Relat Metab Disord       Date:  2003-12

9.  Comparison of serum concentrations of C-reactive protein, TNF-alpha, and interleukin 6 between elderly Korean women with normal and impaired glucose tolerance.

Authors:  K M Choi; J Lee; K W Lee; J A Seo; J H Oh; S G Kim; N H Kim; D S Choi; S H Baik
Journal:  Diabetes Res Clin Pract       Date:  2004-05       Impact factor: 5.602

10.  Rho-associated protein kinase contributes to early atherosclerotic lesion formation in mice.

Authors:  Ziad Mallat; Andrea Gojova; Vincent Sauzeau; Valérie Brun; Jean-Sébastien Silvestre; Bruno Esposito; Régine Merval; Hervé Groux; Gervaise Loirand; Alain Tedgui
Journal:  Circ Res       Date:  2003-10-02       Impact factor: 17.367

View more
  49 in total

1.  In vivo activation of ROCK1 by insulin is impaired in skeletal muscle of humans with type 2 diabetes.

Authors:  Kwang-Hoon Chun; Kang-Duk Choi; Dae-Ho Lee; Yoonshin Jung; Robert R Henry; Theodore P Ciaraldi; Young-Bum Kim
Journal:  Am J Physiol Endocrinol Metab       Date:  2010-12-28       Impact factor: 4.310

Review 2.  Rho/Rho-associated coiled-coil forming kinase pathway as therapeutic targets for statins in atherosclerosis.

Authors:  Naoki Sawada; James K Liao
Journal:  Antioxid Redox Signal       Date:  2013-09-24       Impact factor: 8.401

3.  A method for measuring Rho kinase activity in tissues and cells.

Authors:  Ping-Yen Liu; James K Liao
Journal:  Methods Enzymol       Date:  2008       Impact factor: 1.600

4.  Impaired myocardial blood flow reserve in subjects with metabolic syndrome analyzed using positron emission tomography and N-13 labeled ammonia.

Authors:  Hiroki Teragawa; Koichi Morita; Hiroki Shishido; Nobuaki Otsuka; Yutaka Hirokawa; Kazuaki Chayama; Nagara Tamaki; Yasuki Kihara
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-11-14       Impact factor: 9.236

5.  Attenuation of obesity-induced insulin resistance in mice with heterozygous deletion of ROCK2.

Authors:  H Soliman; J N Varela; V Nyamandi; M Garcia-Patino; G Lin; G R Bankar; Z Jia; K M MacLeod
Journal:  Int J Obes (Lond)       Date:  2016-05-10       Impact factor: 5.095

6.  Rho-associated kinase activity, endothelial function, and cardiovascular risk factors.

Authors:  Junko Soga; Kensuke Noma; Takaki Hata; Takayuki Hidaka; Yuichi Fujii; Naomi Idei; Noritaka Fujimura; Shinsuke Mikami; Tatsuya Maruhashi; Yasuki Kihara; Kazuaki Chayama; Hitoshi Kato; James K Liao; Yukihito Higashi
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-07-07       Impact factor: 8.311

7.  FP-receptor gene silencing ameliorates myocardial fibrosis and protects from diabetic cardiomyopathy.

Authors:  Wen-yuan Ding; Lin Liu; Zhi-hao Wang; Meng-xiong Tang; Yun Ti; Lu Han; Lei Zhang; Yun Zhang; Ming Zhong; Wei Zhang
Journal:  J Mol Med (Berl)       Date:  2014-02-07       Impact factor: 4.599

8.  Exogenous nitric oxide inhibits Rho-associated kinase activity in patients with angina pectoris: a randomized controlled trial.

Authors:  Tatsuya Maruhashi; Kensuke Noma; Noritaka Fujimura; Masato Kajikawa; Takeshi Matsumoto; Takayuki Hidaka; Ayumu Nakashima; Yasuki Kihara; James K Liao; Yukihito Higashi
Journal:  Hypertens Res       Date:  2015-03-05       Impact factor: 3.872

9.  Evidence for statin pleiotropy in humans: differential effects of statins and ezetimibe on rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation.

Authors:  Ping-Yen Liu; Yen-Wen Liu; Li-Jen Lin; Jyh-Hong Chen; James K Liao
Journal:  Circulation       Date:  2008-12-15       Impact factor: 29.690

10.  Two functional polymorphisms of ROCK2 enhance arterial stiffening through inhibiting its activity and expression.

Authors:  Yi-Chu Liao; Ping-Yen Liu; Hsiu-Fen Lin; Wen-Yi Lin; James K Liao; Suh-Hang H Juo
Journal:  J Mol Cell Cardiol       Date:  2014-12-03       Impact factor: 5.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.